Abstract
Editorial: Improving the safety of cell therapy products by suicide gene transfer.
Highlights
With the clinical demonstration of the efficacy of immune checkpoints inhibitors, immunotherapy has been considered in 2013 to be the major breakthrough for cancer therapy (Couzin-Frankel, 2013)
Cell therapy and adoptive cell therapy (ACT), a method based on administration of immunocompetent cells in order to induce a therapeutic response in patients with solid cancer, hematologic malignancies, or immune diseases, have been widely and successfully tested in clinic for the past few years (Rosenberg and Restifo, 2015)
Severe side effects of allogeneic hematopoietic stem cell transplantation (HSCT) or ACT, including the induction of graft-vs.-host disease (GvHD) or on target, off tumor effects limit the use of ACT, prompting researches to improve the safety of cell therapy products
Summary
With the clinical demonstration of the efficacy of immune checkpoints inhibitors, immunotherapy has been considered in 2013 to be the major breakthrough for cancer therapy (Couzin-Frankel, 2013). Many clinical trials have demonstrated the efficiency of genetically modified T cells (GMCs) to treat cancers, including CAR-T cells.
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call